- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05416177
Assessment of Vivity With French Clinical Data Related to the Toric Model Study (VICTOR)
Presbyopia-correcting implant (PC-IOL): AcrySof IQ Vivity (Alcon) has been evaluated in 2 large pivotal trials (US and OUS trials). These tests showed that this PC-IOL restored intermediate visual acuity (IVA) and near visual acuity (NV A) superior to that of the reference monofocal AcrySof implant. In these tests, it was demonstrated that distance visual acuity (DVA) was non-inferior. However, the intermediate visual acuity for this implant in its toric version has not been evaluated.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Le Chesnay, França, 78150
- CH de Versailles
-
Paris, França, 75
- Hôpital Cochin
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Patients will be selected from among patients who come for consultation for cataract surgery. During the inclusion visit, the doctor will inform the patients eligible for the study, and answer all their questions about the objective, the constraints, the foreseeable risks and the expected benefits of the study. Without opposition from the patient, the doctor will perform the cataract surgery and the data will be collected on D0, M1 and M3.
Descrição
Inclusion Criteria:
- Patient presenting for a request for cataract surgery in current practice: phacoemulsification followed by classic implantation of an IOL with small incision size (< 2.2mm)
- Calculated power of IOL is between 10.0 and 30.0 diopters (D) in 0.5D steps to target emmetropia (0.0 +/- 0.5D)
- Patients with corneal astigmatism > 0.5D and who can receive an implant with a toricity between T2 and T6, i.e. with astigmatism between +0.5D and +2.5D.
- If both eyes have astigmatism, the eye under study will be the right eye
- Patient having been informed and not objecting to their participation.
Exclusion Criteria:
- Pregnancy or breastfeeding while conducting the study
- Person under the age of 18
- History of pathologies of the anterior segment of the eye (cornea, anterior chamber, sulcus) or posterior segment of the eye (uvea, vitreous, retina) including retinal vascular occlusions, retinal detachment, peripheral retinal laser photocoagulation, AMD and glaucoma
- Any inflammation of the anterior or posterior segment, whatever its etiology or history of disease, which may lead to an inflammatory reaction
- Clinically significant corneal pathology (epithelial, stromal, or endothelial that could affect visual outcome)
- Clinically significant severe dry eye disease that may affect visual calculations and measurements
- History of refractive surgery
- Amblyopia or monofixation syndrome
- Patient at risk of zonular rupture during the phacoemulsification procedure and may affect the centering or tilt of the implant postoperatively.
- Irregular astigmatism (corneal topography)
- Any other planned eye surgery
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: CASE_ONLY
- Perspectivas de Tempo: PROSPECTIVE
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Distance corrected intermediate monocular visual acuity
Prazo: month 3
|
Intermediate monocular visual acuity (at 66 cm) corrected for distance vision (DCIVA) for the eye under study in photopic condition (normal lighting) 3 months after implantation of the 2nd eye |
month 3
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
rotational stability
Prazo: month 3
|
Rotational stability of the IOL in the eye under study expressed in degree of rotation at 3 months compared with that collected just after surgery in the operating room |
month 3
|
|
residual astigmatism
Prazo: months 1 and 3
|
measure of total residual astigmatism including corneal and internal astigmatism in dioptries |
months 1 and 3
|
|
monocular distance visual acuity
Prazo: months 1 and 3
|
Corrected (BCDVA) and uncorrected monocular distance visual acuity (UCDVA) for the study eye (at 4 m) |
months 1 and 3
|
|
monocular near visual acuity
Prazo: months 1 and 3
|
Corrected (DCNVA) and uncorrected monocular (UCNVA) near visual acuity for the study eye (at 40 cm) |
months 1 and 3
|
|
monocular uncorrected intermediate visual acuity
Prazo: months 1 and 3
|
Uncorrected intermediate visual acuity monocular (UCIVA) for the eye under study (at 66 cm) |
months 1 and 3
|
|
binocular uncorrected visual acuity
Prazo: months 1 and 3
|
Binocular uncorrected visual acuity (UCVA) from far to 4 m, intermediate at 66 cm, near at 40 cm. |
months 1 and 3
|
|
SIA
Prazo: month 3
|
Surgically induced astigmatism (SIA) and comparison between the 2 hospitals participating in the study |
month 3
|
|
questionnaire IOLSAT
Prazo: month 3
|
questionnaire for addiction to glasses for intermediate vision and near vision (IOLSAT) : minimum 0% (no glasses needed, best outcome), to maximum 100% (glasses needed, worse outcome) |
month 3
|
|
McAlinden questionnaire
Prazo: month 3
|
questionnaire for the evaluation of visual disturbances (McAlinden): minimum 0/90 and maximum 90/90 (worse outcome) |
month 3
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- P21/21 - VICTOR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .